CNCR - Loncar Cancer Immunotherapy ETF ETF Analysis | Stock Taper
Logo

CNCR

Loncar Cancer Immunotherapy ETF
Loncar Cancer Immunotherapy ETF
$9.02 1.58% (+0.14)

No price data available
Asset Under Management $12.73M
Inception Date Oct 14, 2015
Expense Ratio 0.79%
52w High $16.27
52w Low $7.88
Volume 3,077
Avg Volume 2,147
Asset Class Equity

About Loncar Cancer Immunotherapy ETF

The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index....

SECTOR HOLDINGS

Healthcare Healthcare
96.58%
Financial Services Financial Services
3.29%
Cash & Others Cash & Others
0.13%

ASSET ALLOCATION BY REGION

United States flag United States
82.79%
Canada flag Canada
3.45%
Netherlands flag Netherlands
3.42%
Denmark flag Denmark
3.42%
United Kingdom flag United Kingdom
3.39%
Switzerland flag Switzerland
3.39%
Other
0.13%